CN1791412A - 新化合物和它们的治疗用途 - Google Patents

新化合物和它们的治疗用途 Download PDF

Info

Publication number
CN1791412A
CN1791412A CNA200480013515XA CN200480013515A CN1791412A CN 1791412 A CN1791412 A CN 1791412A CN A200480013515X A CNA200480013515X A CN A200480013515XA CN 200480013515 A CN200480013515 A CN 200480013515A CN 1791412 A CN1791412 A CN 1791412A
Authority
CN
China
Prior art keywords
alkyl
substituted
aryl
compound
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480013515XA
Other languages
English (en)
Chinese (zh)
Inventor
L·希尔韦莱
N·约翰森
P·科斯基米斯
O·T·彭蒂凯宁
T·尼洛宁
T·A·萨尔米宁
M·S·约翰逊
P·莱赫托沃里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CN1791412A publication Critical patent/CN1791412A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Joining Of Glass To Other Materials (AREA)
CNA200480013515XA 2003-06-10 2004-06-09 新化合物和它们的治疗用途 Pending CN1791412A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47704703P 2003-06-10 2003-06-10
US60/477,047 2003-06-10

Publications (1)

Publication Number Publication Date
CN1791412A true CN1791412A (zh) 2006-06-21

Family

ID=34421462

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480013515XA Pending CN1791412A (zh) 2003-06-10 2004-06-09 新化合物和它们的治疗用途

Country Status (24)

Country Link
US (1) US7465739B2 (https=)
EP (1) EP1635839B1 (https=)
JP (1) JP4605800B2 (https=)
KR (1) KR20060054189A (https=)
CN (1) CN1791412A (https=)
AR (1) AR044650A1 (https=)
AT (1) ATE479437T1 (https=)
AU (1) AU2004277311B8 (https=)
BR (1) BRPI0411295A (https=)
CA (1) CA2527617A1 (https=)
DE (1) DE602004028934D1 (https=)
DK (1) DK1635839T3 (https=)
ES (2) ES2352552T3 (https=)
IL (1) IL172316A0 (https=)
MX (1) MXPA05012745A (https=)
NO (1) NO20060123L (https=)
PL (1) PL1635839T3 (https=)
PT (1) PT1635839E (https=)
RU (1) RU2412190C2 (https=)
SA (1) SA04250159B1 (https=)
SI (1) SI1635839T1 (https=)
TW (1) TWI349551B (https=)
WO (1) WO2005032527A2 (https=)
ZA (1) ZA200508296B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109503572A (zh) * 2017-09-15 2019-03-22 上海交通大学 一种合成吲哚喹啉类化合物的方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US20070232628A1 (en) * 2004-05-06 2007-10-04 Luengo Juan I Calcilytic Compounds
JP2008517061A (ja) * 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
FR2904000A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
CA2772760A1 (en) * 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US10377791B2 (en) 2013-06-25 2019-08-13 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1
KR20160042873A (ko) 2013-06-25 2016-04-20 포렌도 파마 리미티드 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체
WO2014207311A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
CN107207561B (zh) 2014-12-23 2020-03-31 佛恩多制药有限公司 17β-HSD1–抑制剂的前药
US10626140B2 (en) 2014-12-23 2020-04-21 Forendo Pharma Ltd Prodrugs of 17β-HSD1-inhibitors
US20180312493A1 (en) * 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
FI3634975T3 (fi) 2017-06-08 2024-05-03 Organon R&D Finland Ltd 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa
BR112021010598A2 (pt) 2018-12-05 2021-08-24 Forendo Pharma Ltd Compostos, método para preparação de um composto e composição farmacêutica
IL315794A (en) * 2022-04-28 2024-11-01 Enanta Pharm Inc Pyrimidine containing 17-beta-hydrosteroid dehydrogenase type 13 inhibitors
US20250154163A1 (en) * 2023-10-26 2025-05-15 Enanta Pharmaceuticals, Inc. Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (https=) * 1968-06-20 1972-10-25
US3775027A (en) 1971-10-01 1973-11-27 Gray Manuf Co Inc Two-speed pump
JPS62132884A (ja) 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
JP4166433B2 (ja) 1997-09-11 2008-10-15 第一製薬株式会社 ホルモン依存性疾患治療剤
TR200002784T2 (tr) * 1998-03-11 2000-12-21 Endorecherche, Inc Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AU2001296961A1 (en) 2000-09-29 2002-04-08 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
US6750248B2 (en) * 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109503572A (zh) * 2017-09-15 2019-03-22 上海交通大学 一种合成吲哚喹啉类化合物的方法
CN109503572B (zh) * 2017-09-15 2021-10-08 上海交通大学 一种合成吲哚喹啉类化合物的方法

Also Published As

Publication number Publication date
US20050038053A1 (en) 2005-02-17
SA04250159B1 (ar) 2008-06-21
AR044650A1 (es) 2005-09-21
ES2352554T3 (es) 2011-02-21
WO2005032527A3 (en) 2005-08-04
RU2412190C2 (ru) 2011-02-20
AU2004277311B8 (en) 2010-05-27
WO2005032527A2 (en) 2005-04-14
TWI349551B (en) 2011-10-01
AU2004277311B2 (en) 2010-04-29
EP1635839A2 (en) 2006-03-22
PT1635839E (pt) 2010-10-12
KR20060054189A (ko) 2006-05-22
JP4605800B2 (ja) 2011-01-05
BRPI0411295A (pt) 2006-08-01
EP1635839B1 (en) 2010-09-01
PL1635839T3 (pl) 2011-02-28
US7465739B2 (en) 2008-12-16
DE602004028934D1 (de) 2010-10-14
DK1635839T3 (da) 2011-01-03
ATE479437T1 (de) 2010-09-15
ES2352552T3 (es) 2011-02-21
ZA200508296B (en) 2007-01-31
IL172316A0 (en) 2011-08-01
RU2006100033A (ru) 2007-07-20
AU2004277311A1 (en) 2005-04-14
WO2005032527B1 (en) 2005-09-22
TW200509937A (en) 2005-03-16
CA2527617A1 (en) 2005-04-14
NO20060123L (no) 2006-03-09
MXPA05012745A (es) 2006-05-17
SI1635839T1 (sl) 2010-12-31
JP2006527226A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
CN1791412A (zh) 新化合物和它们的治疗用途
CN1264846C (zh) 作为糖原磷酸化酶抑制剂的双环吡咯基酰胺类化合物
CN1177848C (zh) 可用作lh激动剂的二环杂芳族化合物
CN1784234A (zh) 作为17β－羟甾类脱氢酶抑制剂的噻吩嘧啶酮
CN1254474C (zh) 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
CN100345830C (zh) 稠合杂芳基衍生物
CN1167680C (zh) 稠环化合物及其药物用途
CN1308297C (zh) 氨基磺酸苯基酯衍生物
CN1349536A (zh) 噻吩并嘧啶化合物,其制备和应用
CN1106663A (zh) 噻吩并嘧啶衍生物及其制备方法和用途
CN1276790A (zh) 酰胺基噻唑衍生物及其制备方法与药物组合物
CN101061111A (zh) Dna－pk抑制剂
CN1496364A (zh) 取代的喹唑啉衍生物及其作为抑制剂的用途
CN1498212A (zh) 新螺三环衍生物及其作为磷酸二酯酶-7抑制剂的应用
CN1805945A (zh) 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
CN1444570A (zh) 非甾体抗炎药
CN1290164A (zh) 用取代杂环脲抑制raf激酶
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1871236A (zh) 用于治疗5－HT6受体相关病症的新的四氢螺{哌啶－2,7′－吡咯并[3,2－b]吡啶}衍生物和新的吲哚衍生物
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1823071A (zh) 用作钾通道抑制剂的噻吩并嘧啶衍生物
CN1449380A (zh) 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物
CN1849322A (zh) 噻吩并吡唑类化合物
CN1926104A (zh) 作为类固醇激素核受体调节剂的双环取代的吲哚衍生物
CN1878786A (zh) 新的I型17β－羟化类固醇脱氢酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1090565

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1090565

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20060621

C20 Patent right or utility model deemed to be abandoned or is abandoned